The opioid crisis remains one of the most pressing public health challenges in the United States, and the need for accessible, effective treatment for opioid use disorder (OUD) has never been more urgent. Access to Medication-Assisted Treatment (MAT) is critical, yet recent data from the Office of Inspector General (OIG) at the U.S. Department of Health and Human Services (HHS) highlights a serious gap: about one-third of Medicaid enrollees diagnosed with OUD did not receive MAT, such as medication for opioid use disorder (MOUD), as part of their care. This lack of treatment access could be fueling the ongoing opioid epidemic and the alarming rise in opioid-related deaths.
The OIG’s findings shine a light on a troubling reality: while millions of Medicaid enrollees battle opioid addiction, many are unable to access the lifesaving treatments they desperately need. The disparities in access to medication-assisted treatment (MAT) are vast, influenced by geographic location, age, and race. The report underscores the need for immediate action to address these gaps and ensure that all individuals in need of treatment can access it through Medicaid.
The State of Medication for Opioid Use Disorder: A National Overview
The OIG’s investigation into Medicaid enrollees with opioid use disorder in 2021 revealed that approximately 1.5 million Medicaid members experienced OUD during the year. Of these, around 1 million individuals—roughly 67%—received some form of MOUD treatment, including medications like buprenorphine (60%), methadone (33%), or naltrexone (6%). While these treatment options have proven to be effective in reducing opioid use and improving recovery outcomes, the fact that 33% of individuals with OUD did not receive any form of medication for their disorder is alarming.
This gap in treatment is not due to a lack of demand or need. The report suggests that some individuals may have sought treatment outside of Medicaid or paid for care out of pocket, but for many, the treatment options available may not have been medically appropriate. In any case, a significant portion of Medicaid enrollees with OUD is not receiving the standard, evidence-based treatment that could save their lives. This highlights the pressing issue of access to medication-assisted treatment for those in need.
State-by-State Disparities in Access to Medication-Assisted Treatment
One of the most concerning findings in the OIG report is the wide variation in the rates of MOUD use across different states. The differences in access to medication-assisted treatment are stark, with some states offering high levels of care while others fall significantly short. For example, in Rhode Island, nearly 89% of Medicaid enrollees with OUD received MOUD in 2021, making it the state with the highest rate of treatment. In contrast, Illinois had the lowest rate, with just 37% of enrollees receiving the appropriate treatment.
These disparities reveal a troubling trend: some states are providing excellent access to MOUD, while others are failing to meet the needs of their residents struggling with opioid addiction. The OIG report highlights that the gulf between the highest and lowest rates of MOUD use spans a shocking 52 percentage points, further illustrating the need for greater consistency in access to medication-assisted treatment across the country.
In addition to the stark disparities between states, the report notes that less than half of enrollees with OUD in 10 states received MOUD at all. Despite similar rates of opioid use disorder, many of these states have significantly lower rates of MOUD use compared to others. This suggests that factors beyond the prevalence of OUD—such as healthcare infrastructure, state policy, and available treatment options—are playing a role in the treatment gap.
Racial Disparities in Access to Medication for Opioid Use Disorder
Racial disparities are another critical area of concern highlighted in the OIG’s report. Among the 15 states with reliable demographic data, 84% of Medicaid enrollees with OUD were white, while 13% were Black. The remaining enrollees were Asian, Pacific Islander, American Indian, or Alaska Native. However, despite representing a significant portion of the population, Black enrollees experienced the lowest rate of MOUD use at just 53%. White enrollees, on the other hand, had a much higher rate of 71%, slightly above the national average of 67%.
This disparity in access to medication-assisted treatment for Black individuals with OUD is deeply troubling and points to the systemic barriers that many people of color face in accessing healthcare. Research has shown that people of color, especially Black individuals, often encounter numerous obstacles when seeking addiction treatment. These barriers include shortages of MOUD providers in underserved communities, racial discrimination in healthcare settings, and increased stigma surrounding opioid use disorder among minority groups.
These obstacles make it more difficult for Black individuals to access the care they need, which exacerbates the racial and ethnic disparities in opioid treatment outcomes. Furthermore, studies suggest that the stigma associated with opioid use disorder may be even more pronounced for communities of color, further deterring individuals from seeking help.
Age-Related Barriers to Treatment: A Crisis Among Youth
In addition to racial disparities, the report highlights a critical issue regarding age-related barriers to MOUD treatment. Specifically, the report notes that there is a near-complete lack of MOUD treatment for children and adolescents experiencing opioid use disorder. This is a particularly concerning trend given the rising number of overdose deaths among young people in recent years.
Despite the growing opioid epidemic among youth, many providers are hesitant to administer MOUD to minors. Buprenorphine, one of the most common medications for treating OUD, is approved for use in patients aged 16 and older. However, only 24% of residential addiction treatment facilities offer buprenorphine for individuals aged 16 and up. This reluctance to provide treatment to adolescents has left many young people without the necessary care to overcome their addiction.
The report suggests that some providers may be hesitant to treat this age group with MOUD due to its limited approval for individuals under 18. However, the growing number of youth experiencing OUD and opioid overdoses calls for a reevaluation of these hesitations. Pediatric MOUD treatment is a critical gap in the healthcare system that needs immediate attention.
The Call for Action: Reducing Barriers and Expanding Access
The OIG report makes it clear that much work needs to be done to improve access to medication-assisted treatment for individuals with opioid use disorder. To address these disparities, the report urges the Centers for Medicare & Medicaid Services (CMS) to take action to reduce barriers to treatment, particularly for underserved groups. This includes working with state and federal governments to increase Medicaid enrollees’ awareness of MOUD and ensuring that individuals with OUD can access treatment regardless of where they live, their age, or their racial background.
Additionally, the report raises concerns about the potential impact of the end of pandemic-related healthcare flexibilities. If these flexibilities are rolled back, many Medicaid enrollees may find themselves unable to access MOUD, leading to even greater gaps in treatment and care. This emphasizes the critical need to make the access to medication-assisted treatment permanent and reliable for those who need it most.
Conclusion: A Critical Moment in the Fight Against the Opioid Crisis
The opioid epidemic continues to claim lives across the nation, and ensuring access to medication-assisted treatment is essential to reversing this trend. With one-third of Medicaid enrollees with OUD not receiving the treatment they need, it is clear that significant work remains to be done. By addressing the disparities in treatment access—whether they are based on state, age, or race—policymakers and healthcare providers can help to ensure that everyone struggling with opioid addiction has the opportunity to recover and lead a healthier life. Reducing these barriers will not only improve outcomes for individuals but also help to curb the devastating impact of the opioid crisis on communities nationwide.
 is critical, yet recent data from the Office of Inspector General...){kind=link}